BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38412610)

  • 21. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer.
    Kasivisvanathan V; Dufour R; Moore CM; Ahmed HU; Abd-Alazeez M; Charman SC; Freeman A; Allen C; Kirkham A; van der Meulen J; Emberton M
    J Urol; 2013 Mar; 189(3):860-6. PubMed ID: 23063807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men.
    Yarlagadda VK; Lai WS; Gordetsky JB; Porter KK; Nix JW; Thomas JV; Rais-Bahrami S
    Diagn Interv Radiol; 2018; 24(3):115-120. PubMed ID: 29770762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
    Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
    Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
    Leow JJ; Koh SH; Chow MW; Loke W; Salada R; Hong SK; Yeow Y; Lee CH; Tan CH; Tan TW
    Asian J Androl; 2023; 25(1):43-49. PubMed ID: 35488666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
    Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
    J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate.
    Bonekamp D; Schelb P; Wiesenfarth M; Kuder TA; Deister F; Stenzinger A; Nyarangi-Dix J; Röthke M; Hohenfellner M; Schlemmer HP; Radtke JP
    Eur Radiol; 2019 Apr; 29(4):1820-1830. PubMed ID: 30327861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study.
    Ahdoot M; Lebastchi AH; Long L; Wilbur AR; Gomella PT; Mehralivand S; Daneshvar MA; Yerram NK; O'Connor LP; Wang AZ; Gurram S; Bloom J; Siddiqui MM; Linehan WM; Merino M; Choyke PL; Pinsky P; Parnes H; Shih JH; Turkbey B; Wood BJ; Pinto PA;
    Eur Urol Oncol; 2022 Apr; 5(2):176-186. PubMed ID: 33846112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Prostate HistoScanning as a Method for Targeted Biopsy in Routine Practice.
    Glybochko PV; Alyaev YG; Amosov AV; Krupinov GE; Nir D; Winkler M; Ganzha TM
    Eur Urol Focus; 2019 Mar; 5(2):179-185. PubMed ID: 28753891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
    Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
    J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
    Siddiqui MM; Rais-Bahrami S; Truong H; Stamatakis L; Vourganti S; Nix J; Hoang AN; Walton-Diaz A; Shuch B; Weintraub M; Kruecker J; Amalou H; Turkbey B; Merino MJ; Choyke PL; Wood BJ; Pinto PA
    Eur Urol; 2013 Nov; 64(5):713-719. PubMed ID: 23787357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
    Prendeville S; Gertner M; Maganti M; Pintilie M; Perlis N; Toi A; Evans AJ; Finelli A; van der Kwast TH; Ghai S
    J Urol; 2018 Jul; 200(1):104-113. PubMed ID: 29408568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fourteen-Core Systematic Biopsy That Includes Two Anterior Cores in Men With PI-RADS Lesion ≥ 3 is Comparable With Magnetic Resonance Imaging-ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer: A Single-institution Experience.
    Sterling J; Smith K; Farber N; Nagaya N; Jang TL; Singer EA; Sadimin E; Kim IY
    Clin Genitourin Cancer; 2021 Aug; 19(4):275-279. PubMed ID: 33153920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
    Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
    Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions.
    Siddiqui MM; George AK; Rubin R; Rais-Bahrami S; Parnes HL; Merino MJ; Simon RM; Turkbey B; Choyke PL; Wood BJ; Pinto PA
    J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27130933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy-Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?
    Dimitroulis P; Rabenalt R; Nini A; Hiester A; Esposito I; Schimmöller L; Antoch G; Albers P; Arsov C
    J Urol; 2018 Nov; 200(5):1030-1034. PubMed ID: 29733837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
    Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
    Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy.
    Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Tian Z; Karakiewicz PI; Tilki D; Fisch M; Maurer T; Graefen M; Budäus L
    J Urol; 2020 Feb; 203(2):299-303. PubMed ID: 31483694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.